Royalty Pharma plc

NASDAQ:RPRX

27.99 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 537.267567.978596536.313538.202683.971565.748573.463535.955562.049575.7585.773554.963573.027571539510.932500.879457.486464.277457.608434.883
Cost of Revenue 6583.676.513277.137241.228118.8045.67305.061105.7145.67266.5055.7965.7335.671129.3415.7965.73388.012919.16122.33872.2150.033
Gross Profit 531.267-15.622519.487259.176296.974565.167560.078268.402430.241556.379309.195579.977549.23567.356441.659533.204505.199412.867-461.674341.939385.398384.85
Gross Profit Ratio 0.989-0.0280.8720.4830.5520.8260.990.4680.8030.990.5370.990.990.990.7730.9890.9890.824-1.0090.7360.8420.885
Reseach & Development Expenses 0.50.5150.50.50.550.525.50.606100.5103.82190.53.1222.641855.7767.63915.8722.71821.45722.991
General & Administrative Expenses 54.70857.65259.18557.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Selling & Marketing Expenses 0.2920-0.1850000000000000000000
SG&A 54.70857.6525957.23447.63485.69573.22850.69251.84351.5446.16148.58844.92143.156505142.79938.06523.06125.60330.34924.426
Other Expenses -212.429-583.677-1.7071.091118.804308.848305.061105.714190.291-4.82-0.793-0.1070.043801310.261-5.9230.140.232-0.0370.058
Operating Expenses 267.637641.752-17384.871289.362204.999432.576381.253158.163342.331422.283282.721-189.986343.7325828101.586139.449-874.433-68.221129.7493.983
Operating Income 269.63-73.774613151.442248.84478.97295.339192.21227.642219.718153.417303.052744.949229.297314511409.346361.431,331.919532.498327.859430.9
Operating Income Ratio 0.502-0.131.0290.2820.4620.70.1690.3350.4250.3910.2660.5171.3420.40.550.9480.8010.7222.9111.1470.7160.991
Total Other Income Expenses Net -75.25369.501105-6.768123.79230.117-705.36928.204263.955-91.635-63.411-49.1985.195-49.50190145224.095-201.608174.705-28.256-84.39522.433
Income Before Tax 194.377-4.273718122.077351.336509.089-610.03220.414491.597128.08353.671221.796806.755158.979367624601.976109.0961,446.528440.027178.77396.094
Income Before Tax Ratio 0.362-0.0081.2050.2280.6530.744-1.0780.3840.9170.2280.0930.3791.4540.2770.6431.1581.1780.2183.1620.9480.3910.911
Income Tax Expense 92.373-9.05122349.963123.711168.3340.1392.582187.093167.95746.974119.867365.97989.86-531.38333.622159.90276.44378.81392.03188.04490.445
Net Income 102.0044.778494.3472.114227.625340.755-610.169217.832304.504-39.8747.904101.929440.77669.119171291442.07471.241,420.396408.982151.713367.444
Net Income Ratio 0.190.0080.8290.1340.4230.498-1.0790.380.568-0.0710.0140.1740.7940.1210.2990.540.8650.1423.1050.8810.3320.845
EPS 0.230.0111.110.160.510.76-1.380.360.5-0.0660.0160.241.080.180.440.790.090.24.011.150.431.04
EPS Diluted 0.230.0111.110.160.50.76-1.380.360.5-0.0660.0110.241.080.180.440.790.090.24.011.150.431.04
EBITDA 269.63-73.774613167.949274.814527.467169.004192.195388.413233.557127.01323.065782.313249.691411661447.356355.0241,330.3535.065329.885442.055
EBITDA Ratio 0.502-0.131.0290.3130.5110.7710.2990.3350.7250.4160.2210.5521.410.4360.721.2260.8760.7092.9081.1520.7211.016